About ADDS

2nd ACE DRUG DISCOVERY SUMMIT

20th - 21st MARCH, 2024

WEDNESDAY-THURSDAY

THE INSURANCE HALL LONDON, UK

About 2nd ADDS

2nd ACE Drug Discovery Summit, 2024 provides a platform for scientists, researchers and decision makers from all over the world to debate on the latest scientific advances, trends, current challenges and futuristic advancements in Drug Discovery. The two day conference is designed to maximize collaborations and innovation with pharma and technology presentations, interactive sessions by professionals from industry and academia. The Summit features talks on the cutting edge of the discipline that include latest scientific advancements in the areas of drug discovery, AI, screening automation, high content imaging, disease modelling, cell and gene therapy and more. Summit will be attracting senior strategic decision-makers with top-level speakers, interactive round-tables, knowledge-sharing panel sessions, in-depth workshops and superb networking. Join us at 2nd ACE Drug Discovery, 2024 to meet scientists from around the world and to learn how to move pharma from the bench to the market. We look forward to your contribution!

Why Attend

ADDS Thought Leaders

GERHARD MÜELLER

CSO | Anavo Therapeutics


LUTZ MUELLER

Distinguished Scientist – Project Leader | Roche

NAHUEL VILLEGAS

CSO | Vivan Therapeutics


DUYGU YILMAZ

Principal Scientist | Ochre Bio

 

ELIOTT HARFOUCHE

Partner | Nodes Advisors AG


ANDREW BUCHANAN

Principal | AstraZeneca


PAUL FINN

Chief Scientific Officer | Oxford Drug Design

NORMAN MILLER

Cofounder and CSO | Kutanios Ltd


JONATHAN MASON

Senior Research Fellow / Head Computational Chemistry | Sosei Heptares / Orexia Therapeutics

CHRYSI SERGAKI


Microbiome Group Leader | Medicines and Healthcare products Regulatory Agency

ISTVAN (J) ENYEDY


Senior Director Computational Chemistry | Theseus Pharmaceuticals

JUANA LUCIA FLORES CANDIA

Board Member | LeadXpro


PATRIZIA D’ALESSIO

CEO | AISA Therapeutics

ANDREAS SEIDL

CSO | Formycon AG

ASIF AHMED

Executive Chairman & CEO | MirZyme Therapeutics

SUBHADRA DRAVIDA

Founder & CEO |
Transcell Biologics

MARTA FREITAS

Principal Scientist, Quality Control | Quell Therapeutics

HELEN LOCK

Principal Scientist |
Quell Therapeutics

MIROSLAV GASPAREK

Co-Founder and CEO |
Sensible Biotechnologies

NAJY ALSAYED

Global Head of disease area | Manarini Group

WILLIAM DONALDSON


President & CEO | Estrigenix Therapeutics

AGOSTINO MARASCO


Head of Chemistry Italy | Autifony Therapeutics Limited

MARIE-CHRISTINE PARDON

Assistant Professor in Translational Neuroscience | University of Nottingham

BEN DOAK


Head of Innovative Treatments | NHS England

0 +
Attendees
0 +
Speakers
0 +
Companies
0 +
Networking Hours

Solutions at ADDS

🔷 Antibody Engineering
🔷 ADMUPI (Toxicology)
🔷 Covering Biological studies
🔷 Discovery Outsourcing Services
🔷 Drug Discovery Technology Platforms
🔷 High Throughput Screening
🔷 Licensing
🔷 ln licensing/out licensing discovery                   projects proprietary technologies
🔷 PK/PD
🔷 Protein identification Services
🔷 Screening and Profiling Services
🔷 Transgenisis Services

🔷 Biochemistry
🔷 Biomarker Validation
🔷 Data Management Technology
🔷 DNA & RNA Analysis
🔷 Gene Expression Profiling Solutions
🔷 Lead Generation
🔷 lmaging/biomarker service/collaboration
🔷 Medicinal Chemistry
🔷 Pharmacogenetic Testing
🔷 Preclinical
🔷 Research & Development
🔷 Structural Biology

🔷 Bio-informatics
🔷 Combinatorial Chemistry
🔷 Digital lmaging Technology
🔷 DNA Sequencing Services
🔷 Genomics
🔷 Lead Optimatisation and Profiling, HTS             Technology
🔷 Molecular Biology
🔷 Pharmacology
🔷 Principal Scientists
🔷 Reagents Technology
🔷 Target identification & Validation

Who Will Attend

🔷 CEO
🔷 Director of Discovery Strategy Portfolio
🔷 Head of DMPK
🔷 Head of R&D Licensing
🔷 Senior Director Discovery Research
🔷 VP of Chemistry
🔷 VP Translational Medicine

🔷 CSO
🔷 Director of Screening & Compound Profiling
🔷 Head of Drug Design
🔷 Head Pharmacology & Toxicology
🔷 Senior Director Function Genomics
🔷 Head Pharmacology & Toxicology

🔷 Director Discovery Alliances
🔷 Executive Director Chemistry
🔷 Head of Molecular Toxicology
🔷 Principal Scientist
🔷 VP & Director of Drug Discovery
🔷 VP Target Discovery & Assessment

Attendee Breakdown

Attendee Demographics

Agenda

🔷 08:45 – 09:00 Chairman’s Welcome Remarks

🔷 09:00 – 09:30 Presentation no.1:

AI in Drug Discovery: What is realistic, what are illusions what happened, Didn’t happen, and what still needs to happen?

  • Review recent developments in the field of artificial intelligence in drug discovery
  • Discuss their likely impact on project outcomes in the near future
  • over the aspect of model validation and the impact of ‘AI’ on the transition of compounds to the in vivo stages

Buyers 2024 Pharma / Biotech

To view this protected content, enter the password below:

if you dont have password. Contact us at [email protected]

Our Sponsors

Our Partners

Media Partners

Venue - The Insurance Hall

The Insurance Hall has been the home of the UK conference industry for over 80 years. It is a prestigious and impressive event venue steeped in history, heritage and architectural significance, a hidden gem in one of the City of London’s most decorated buildings. A Grade II listed building formally opened by His Majesty King George V in 1934, The Insurance Hall offers exceptional and flexible event spaces for conferences, receptions, AGMs, business breakfasts, meetings, lunches and dinners for up to 300 people.

SPONSORSHIP OPPORTUNITIES

If you wish to inquire about sponsorship prospects, kindly reach out to:

Taha Bilal

Head of Sales

SPEAKER / DELEGATE OPPORTUNITIES

If you wish to inquire about speaking opportunities, and to book attendee pass, kindly reach out to:

Huma Taha

Head of Marketing

     : [email protected]